实验室管理:将临床结局与合理检验利用关联以提升临床化学实验室诊疗质量
该综述基于国际临床化学与检验医学联合会(IFCC)实验室医学结局研究工作组(TF-OSLM)的结局分类框架,审视临床化学检验的管理策略,聚焦红细胞沉降率/C反应蛋白联合开具、心肌肌钙蛋白与旧标志物、维生素D检测三个高影响靶点,发现强证据支持检验量下降与成本节约,但干预与患者层面临床结局的直接证据仍有限。
要点
- IFCC TF-OSLM框架将结局分为七类,可迁移用于其他高通量临床化学检验。
- 三个靶点均有强证据支持检验量下降和机构及国家层面成本节约。
- 干预与死亡率或诊断轨迹等患者层面结局的直接证据仍有限。
核心结论
- 临床化学检验管理策略在降低检验量和成本方面证据强,但与患者层面临床结局的直接关联证据仍有限。
研究设计与样本
- 综述采用IFCC TF-OSLM基于结局的框架,将结局分为患者管理变化、临床结局、经济学、运营效率、以患者为中心、安全性和政策制定七类。
- 综述聚焦红细胞沉降率/C反应蛋白联合开具、心肌肌钙蛋白与旧标志物、维生素D检测三个高影响靶点。
主要发现
- 三个靶点均有强证据支持机构和国家级检验量下降及相关成本节约。
- 干预与死亡率或诊断轨迹等患者层面临床结局的直接证据仍有限。
- 安全性数据限于回顾性观察,多数证据来自大型学术中心。
- 媒体和健康文化驱动的公众检测需求可削弱稳健政策干预的效果。
临床怎么用
- 管理项目应在利用指标之外纳入对临床结局的前瞻性评估,以构建基于结局的实验室医学质量证据基础。
- TF-OSLM框架可迁移用于其他高通量临床化学检验的管理策略评估。
局限性
- 干预与患者层面临床结局的直接证据有限。
- 安全性数据限于回顾性观察。
- 多数证据来自大型学术中心,外推性受限。
- 公众检测需求可能削弱政策干预效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stewardship of laboratory services aims to ensure appropriate test utilization and improve patient outcomes. However, clinical chemistry initiatives have largely focused on reducing test volumes and costs rather than linking interventions to clinical outcomes. This review examines stewardship strategies for clinical chemistry tests using an outcome-based framework developed by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on Outcome Studies in Laboratory Medicine (TF-OSLM), which classifies outcomes into seven categories: change in patient management, clinical outcomes, economics, operational efficiencies, patient-centeredness, safety, and guide policy making. We review stewardship evidence for three high-impact targets: erythrocyte sedimentation rate/C-reactive protein co-ordering, cardiac troponin with legacy markers, and vitamin D testing. For each target, we summarize the clinical context, intervention strategies, and outcomes mapped to the TF-OSLM framework. Across all three targets, strong evidence supports reductions in test volume and associated cost savings at the institutional and national levels. However, a consistent gap emerges: direct evidence linking these interventions to patient-level clinical outcomes, such as mortality or diagnostic trajectories, remains limited. Safety data remain limited to retrospective observations, and most evidence stems from large academic centers. Public demand for testing, driven by media and wellness culture, poses an additional challenge that can undermine even robust policy interventions. The TF-OSLM framework is readily transferable to other high-volume clinical chemistry tests, and stewardship programs should incorporate prospective evaluation of clinical outcomes alongside utilization metrics to build a comprehensive evidence base for outcome-based quality in laboratory medicine.
引用
- Park K, Don-Wauchope AC. Laboratory Stewardship: Improving Quality of Care by Linking Clinical Outcomes to Appropriate Test Utilization in Clinical Chemistry Laboratories. Ann Lab Med. 2026. PMID: 42702929. doi:10.3343/alm.2026.0193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。